Chongqing Zhifei Biological Products Co.Ltd(300122) april 27 announced the 2021 annual report and the first quarterly report of 2022 at the same time. Last year, the company achieved an operating revenue of 30.652 billion yuan, a year-on-year increase of 101.79%; The net profit attributable to the parent company was 10.209 billion yuan, a significant increase of 209.23% year-on-year; The net profit after deducting non profit was 10.184 billion yuan, an increase of 206.48%, and the earnings per share was 6.38 yuan. The company’s profit distribution plan for the 21st year is to pay out 6 yuan (including tax) for every 10 shares.
From January to March this year, the company’s performance continued to maintain rapid growth, realizing an operating revenue of 8.841 billion yuan, a year-on-year increase of 125.16%; The net profit attributable to the parent company was 1.923 billion yuan, a year-on-year increase of 104.95%; The net profit after deducting non profit was 1.896 billion yuan, an increase of 101.15%, and the earnings per share was 1.20 yuan. The company said that during the reporting period, the cooperation with MSD was in normal progress, and the number of batches of agency products increased significantly year-on-year, including 2.11 million tetravalent HPV vaccines, an increase of nearly 70%; Nine valent HPV vaccines were issued in batches of 4.83 million, an increase of nearly 280%; 3.24 million pentavalent rotavirus vaccines were issued in batches, an increase of nearly 220%; 48 Shenzhen Universe (Group) Co.Ltd(000023) valent pneumonia vaccines were issued in batches, an increase of more than 100%.
It is understood that in 2021, the company continued to practice the corporate purpose of “social benefit first and enterprise benefit second”, guaranteed the R & D progress and production supply of covid-19 vaccine and other products, increased R & D investment, innovated R & D technology, continued to work closely around the business development objectives, and achieved sustained growth of business performance through the “technology + market” two wheel driven development model.
In March, 2021, the company’s recombinant novel coronavirus protein vaccine (CHO cell) (zhikeweide) was included in the emergency use, serving the implementation of the national mass immunization plan, and was approved for emergency use in many countries. During the year, it provided protection for more than 100million people. In June, the company’s own product Mycobacterium vaccae (micro card) for injection was approved to increase the indications, add new prevention of pulmonary tuberculosis in people with latent infection of Mycobacterium tuberculosis, and jointly build a “diagnosis, prevention and treatment” system of pulmonary tuberculosis with recombinant Mycobacterium tuberculosis fusion protein (EC) (Yika). Up to now, wechat has won the bid in 25 provincial units, and the bidding and product promotion in other regions are also actively promoted.
At the same time, the company has also actively done a good job in product import, promotion and sales, and is committed to improving product supply together with moshadong to meet the needs of national disease prevention. The number of batches of agency products increased significantly year-on-year, including 8.8025 million tetravalent HPV vaccines, an increase of 21.93%; The annual batch issuance of nine valent HPV vaccine was 102062 million, an increase of 101.45%; The annual batch issuance of pentavalent rotavirus vaccine was 7.3086 million, an increase of 83.02%; The number of 23 valent pneumonia vaccines issued in batches throughout the year was 1.4757 million, an increase of 208.40%; Inactivated hepatitis A vaccine was issued in batches throughout the year, with an increase of 67.44%.
In addition, three products under development, namely freeze-dried rabies vaccine for human use (Vero cells), bivalent Shigella flexneri conjugate vaccine and acyw135 group meningococcal conjugate vaccine, have entered phase III of clinical trial; Two products under development, namely DPT vaccine and inactivated rotavirus vaccine, have entered phase I of clinical trial. During the year, the company’s R & D investment reached 814 million yuan, a year-on-year increase of 69.38%. By the end of the 21st century, the company had 29 independent R & D projects, including 16 projects in the stage of clinical trial and application for registration.
In order to introduce the R & D achievements into the market as soon as possible, the company has also significantly increased the allocation of sales personnel and established a broader sales network. In 2021, the company’s sales personnel reached 2817, with a year-on-year increase of 48%; By the end of the year, the marketing network had covered 31 provinces, autonomous regions and municipalities directly under the central government, more than 300 prefectures and cities, more than 2600 districts and counties and more than 30000 grass-roots health service points, providing an effective guarantee for the company’s timely, accurate and in-depth market services.
Looking forward to the future, Chongqing Zhifei Biological Products Co.Ltd(300122) said that it would actively seize the opportunity, implement the new development concept, actively expand the layout of the large biological field while deepening the main industry of vaccines, boost the development of enterprises with scientific research and innovation, and strive to become a first-class enterprise with excellent products, outstanding brands, leading innovation, modern governance and international competitiveness.
Therefore, in 2022, the company will accelerate research and development, actively layout cutting-edge technologies and accelerate the progress of pipeline under research; Grasp substantive control, ensure product quality, and lay a solid foundation for product internationalization strategy; Refine services, optimize market operations, and reach and cover more people and more terminals; Continue to strengthen compliance construction to ensure that the company’s production, R & D, sales and promotion are carried out in compliance and order; Based on China, explore global opportunities and continue to promote the export of high-quality products overseas.
